23rd Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS)
&
12th Annual Conference of Rehabilitation in MS (RIMS)
11.10.2007 - 14.10.2007

Please select a day:

Personal programme

Please enter your email address here in order to bring up your personal programme

Home

Saturday, October 13, 2007

- Click on a checkbox to select a whole session.
- Session titles which are underlined can be clicked upon to show further details.
- Individual programme items can also be selected.
- Go to another day to select further points or click on display to show your saved personal programme.

	09:00	The challenges of evidence-based medicine in neurorehabiliation (Plenary session 2 RIMS/ECTRIMS)
	10:30	Haematopoetic stem cells in MS (Parallel session 5)
	10:30	Imaging repair (Parallel session 6)
	12:45	Therapeutic strategies in MS: from neurogenesis to long-term efficacy (Teva Sanofi Aventis satellite)
	14:00	Update on new treatments (Parallel session 7)
	14:00	Recent failures and successes of biomarkers in MS (Parallel session 8)
	14:00	Free communications (RIMS session 3)
	15:30	Immunology 2 (Poster topic 13)
	15:30	Immunomodulation 2 (Poster topic 14)
	15:30	Imaging 2 (Poster topic 15)
	15:30	Genetics and transcriptomics (Poster topic 16)
	15:30	MS variants (Poster topic 17)
	15:30	Clinical assessment tools (Poster topic 18)
	15:30	Differential diagnosis (Poster topic 19)
	15:30	Neuropsychology (Poster topic 20)
	15:30	Immunosuppression (Poster topic 21)
	15:30	Neurobiology (Poster topic 22)
	15:30	Experimental models (Poster topic 23)
	15:30	Economic burden (Poster topic 24)
	15:30	Quality of life (Poster topic 25)
	17:00	Homogeneity versus heterogeneity in MS: stage-dependent or patient-dependent? (Hot topics in MS 4)
	17:00	Management of side effects and dangers of immunotherapies (Hot topics in MS 5)
	17:00	T-reg cells in MS (Hot topics in MS 6)
	18:00	S1P receptor modulation: targeting peripheral and central mechanisms in MS (Novartis Pharma satellite)
	19:15	Care-MS: the clinical development programme for alemtuzumab in multiple sclerosis (Bayer Schering & Genzyme)